Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

Weaning patients with less-potent topical corticosteroids (10/0 hydrocortisone or desonide cream) or topical calcineurin inhibitors (1% pimecrolimus) may minimize flares (Oppel, Pavicic ...

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / January 9, 2025 / CAGE Bio, Inc., a clinical-stage biotechnology company advancing innovative ...

Opens in a new tab or window Tapinarof 1% topical cream showed greater efficacy than the control in adults and children as young as age 2 years with atopic dermatitis (AD). The cream also provided ...

The FDA approved tapinarof cream 1% (VTAMA; Organon) today to treat patients aged 2 and older with atopic dermatitis. Ahead of its extended target action date of March 12, 2025, the FDA approved ...

“We tend to give ointment for dry conditions and ... on symptoms for each type and expert advice on the best way to manage ...

“With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there is now a therapy that offers the potential for powerful skin clearance with ...

More patients treated with Vtama achieved vIGA-AD success compared with those who received vehicle cream in both ADORING 1 (45% vs 14%) and ADORING 2 (46% vs 18%). The Food and Drug Administration ...

CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...